Carmot Therapeutics Highlights Clinical Data from its : vima

– CT-388 administered once-weekly resulted in clinically meaningful weight loss and insulin sensitivity over a 4 week treatment period in participants with...

Related Keywords

Dallas , Texas , United States , , Carmot Therapeutics Inc , Manu Chakravarthy , Chief Scientific , Improved Insulin Sensitivity , Novel Dual , Carmot Therapeutics , Ct 388 , Ct 868 , Lp 1 Gip , Etabolicdisease ,